No Association Between BMI and Immunotoxicity or Clinical Outcomes for Immune Checkpoint Inhibitors

References

• Cortellini A , RicciutiB , TiseoMet al. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. J. Immunother. Cancer8(2), e001403 (2020).
   PubMed Web of Science ®Google Scholar
• Cortellini A , BersanelliM , ButiSet al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J. Immunother. Cancer7(1), 57 (2019).
   PubMed Web of Science ®Google Scholar
• Rogado J , Romero-LaordenN , Sanchez-TorresJMet al. Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies. Oncoimmunology9(1), 1751548 (2020).
   PubMed Web of Science ®Google Scholar
• Richtig G , HoellerC , WolfMet al. Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study. PLoS One13(10), e0204729 (2018).
   PubMed Web of Science ®Google Scholar
• Jin J , StabileLP. When fat is favorable: the unexpected relationship between obesity and response to immunotherapy. Immunotherapy12(14), 1035–1039 (2020).
   PubMed Web of Science ®Google Scholar
• Nie RC , ChenGM , WangYet al. Association between body mass index and survival outcomes in patients treated with immune checkpoint inhibitors: meta-analyses of individual patient data. J. Immunother.44(9), 371–375 (2021).
   PubMed Web of Science ®Google Scholar
• Francisco V , PinoJ , Campos-CabaleiroVet al. Obesity, fat mass and immune system: role for leptin. Front. Physiol.9, 640 (2018).
   PubMed Web of Science ®Google Scholar
• Wang Z , AguilarEG , LunaJIet al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat. Med.25(1), 141–151 (2019).
   PubMed Web of Science ®Google Scholar
• Iyengar NM , GucalpA , DannenbergAJ , HudisCA. Obesity and cancer mechanisms: tumor microenvironment and inflammation. J. Clin. Oncol.34(35), 4270–4276 (2016).
   PubMed Web of Science ®Google Scholar
• Johannet P , SawyersA , QianYet al. Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer. J. Immunother. Cancer8(2), e001674 (2020).
   PubMed Web of Science ®Google Scholar
• Young AC , QuachHT , SongHet al. Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma. J. Immunother. Cancer8(2), e000821 (2020).
   PubMed Web of Science ®Google Scholar
• De Giorgi U , ProcopioG , GiannarelliDet al. Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. Clin. Cancer Res.25(13), 3839–3846 (2019).
   PubMed Web of Science ®Google Scholar
• Popinat G , CousseS , GoldfarbLet al. Subcutaneous fat mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab. Oncoimmunology8(5), e1580128 (2019).
   PubMed Web of Science ®Google Scholar
• Zhou X , YaoZ , YangH , LiangN , ZhangX , ZhangF. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med.18(1), 87 (2020).
   PubMed Web of Science ®Google Scholar
• Cortellini A , BersanelliM , SantiniDet al. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events. Eur. J. Cancer128, 17–26 (2020).
   PubMed Web of Science ®Google Scholar
• McQuade JL , DanielCR , HessKRet al. Association of body mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol.19(3), 310–322 (2018).
   PubMed Web of Science ®Google Scholar
• Caan BJ , MeyerhardtJA , KroenkeCHet al. Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C-SCANS study). Cancer Epidemiol. Biomarkers Prev.26(7), 1008–1015 (2017).
   PubMed Web of Science ®Google Scholar
• NIH . Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (2021). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
   Google Scholar
• Labadie BW , LiuP , BaoRet al. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. J. Transl. Med.17(1), 386 (2019).
   PubMed Web of Science ®Google Scholar
• Indini A , RijavecE , GhidiniMet al. Impact of BMI on survival outcomes of immunotherapy in solid tumors: a systematic review. Int. J. Mol. Sci.22(5), 2628 (2021).
   PubMed Web of Science ®Google Scholar
• Eun Y , KimIY , SunJMet al. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci. Rep.9(1), 14039 (2019).
   PubMedGoogle Scholar
• Kichenadasse G , MinersJO , MangoniAA , RowlandA , HopkinsAM , SorichMJ. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol.6(4), 512–518 (2020).
   PubMed Web of Science ®Google Scholar
• Ichihara E , HaradaD , InoueKet al. The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. Lung Cancer139, 140–145 (2020).
   PubMed Web of Science ®Google Scholar
• Martini DJ , LiuY , ShabtoJMet al. Novel risk scoring system for patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Oncologist25(3), e484–e491 (2020).
   PubMed Web of Science ®Google Scholar
• Martini DJ , KlineMR , LiuYet al. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer126(3), 575–582 (2020).
   PubMed Web of Science ®Google Scholar
• Takada K , TakamoriS , YoneshimaYet al. Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. Lung Cancer145, 18–26 (2020).
   PubMed Web of Science ®Google Scholar
• Lalani AA , BakounyZ , FarahSet al. Assessment of Immune checkpoint inhibitors and genomic alterations by body mass index in advanced renal cell carcinoma. JAMA Oncol.7(5), 773–775 (2021).
   PubMed Web of Science ®Google Scholar
• Daly LE , PowerDG , O’ReillyAet al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br. J. Cancer116(3), 310–317 (2017).
   PubMed Web of Science ®Google Scholar
• Rutkowski P , IndiniA , DeLuca Met al. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. J. Immunother. Cancer8(2), e001117 (2020).
   PubMed Web of Science ®Google Scholar
• Donnelly D , BajajS , YuJet al. The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients. J. Immunother. Cancer7(1), 222 (2019).
   PubMed Web of Science ®Google Scholar
• Shiroyama T , SuzukiH , TamiyaMet al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med.7(1), 13–20 (2018).
   PubMed Web of Science ®Google Scholar
• Rassy EE , GhosnM , RassyNA , AssiT , RobertC. Do immune checkpoint inhibitors perform identically in patients with weight extremes?Immunotherapy10(9), 733–736 (2018).
   PubMed Web of Science ®Google Scholar
• Chen H , WangD , ZhongQ , TaoY , ZhouY , ShiY. Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol. Immunother.69(12), 2413–2424 (2020).
   PubMed Web of Science ®Google Scholar
• An Y , WuZ , WangNet al. Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J. Transl. Med.18(1), 235 (2020).
   PubMed Web of Science ®Google Scholar
• Guzman-Prado Y , BenShimol J , SamsonO. Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis. Cancer Immunol. Immunother.70(1), 89–100 (2021).
   PubMed Web of Science ®Google Scholar
• Hsiehchen D , WattersMK , LuR , XieY , GerberDE. Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors. JAMA Netw. Open2(9), e1911519 (2019).
   PubMed Web of Science ®Google Scholar
• Sanchez A , FurbergH , KuoFet al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol.21(2), 283–293 (2020).
   PubMed Web of Science ®Google Scholar
• Malietzis G , AzizO , BagnallNM , JohnsN , FearonKC , JenkinsJT. The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: a systematic review. Eur. J. Surg. Oncol.41(2), 186–196 (2015).
   PubMed Web of Science ®Google Scholar
• Naik GS , WaikarSS , JohnsonAEWet al. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J. Immunother. Cancer7(1), 89 (2019).
   PubMed Web of Science ®Google Scholar
• Freshwater T , KondicA , AhamadiMet al. Evaluation of dosing strategy for pembrolizumab for oncology indications. J. Immunother. Cancer5, 43 (2017).
   PubMed Web of Science ®Google Scholar
• Walker S , LeseleucL , ButcherR. CADTH technology review: optimal use 360 report: dosing and timing of immuno-oncology drugs (2019). www.cadth.ca/sites/default/files/ou-tr/ho0008-dosing-timing-immuno-oncology-drugs.pdf
   Google Scholar
• Finelli C . Obesity and immunotherapy: the surprisingly positive association!Immunotherapy12(8), 541–544 (2020).
   PubMed Web of Science ®Google Scholar
• Bergerot PG , BergerotCD , PhilipEJet al. Targeted therapy and immunotherapy: effect of body mass index on clinical outcomes in patients diagnosed with metastatic renal cell carcinoma. Kidney Cancer3(1), 63–70 (2019).
   Google Scholar